Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM 4701

Next Previous
X
Search
Drug Profile

IMM 4701

Alternative Names: IMM-4701

Latest Information Update: 07 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneOnco Biopharma
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD24 antigen inhibitors; CD47 antigen inhibitors; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 07 Sep 2022 ImmuneOnco Biopharma has patents pending for IMM 4701 in China, Japan, USA and European Union
  • 07 Sep 2022 Preclinical trials in Solid tumours in China (Parenteral), as of September 2022 (ImmuneOnco Biopharma, September 2022)
  • 07 Sep 2022 ImmuneOnco Biopharma plans to file IND applications with the NMPA and the FDA for the treatment of Solid tumours, prior to September 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top